Serendipity: How the search for meaning of serum uric acid might lead to the repurposing of an old drug in patients with cardiovascular disease

Nidorf, Mark; Jelinek, Michael

doi:10.1177/2047487317749039

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AF, atrial fibrillation; BP, blood pressure; CAC, coronary artery calcium; CHD, coronary heart disease; CT, computed tomography; CVD, cardiovascular disease; EOCAD, early-onset coronary artery disease; HF, heart failure; LV, left ventricle; RCT, randomized controlled trial; sUA, serum uric acid; T2D, type 2 diabetes; UA, uric acid; ULT, uric acid-lowering treatments. MacIsaac et al, 2016;Singh et al, 2017;Nidorf and Jelinek, 2018;Singh and Cleveland, 2018). For drugs promoting the excretion of UA, benzbromarone is superior to probenecid in efficacy and safety.…”

Section: Urate-lowering Treatments (Ult)mentioning

confidence: 99%

Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective

2020

View full text Add to dashboard Cite

Uric acid (UA) is the end product of purine nucleotide metabolism in the human body. Hyperuricemia is an abnormally high level of UA in the blood and may result in arthritis and gout. The prevalence of hyperuricemia has been increasing globally. Epidemiological studies have shown that UA levels are positively correlated with cardiovascular diseases, including hypertension, atherosclerosis, atrial fibrillation (AF), and heart failure (HF). Hyperuricemia promotes the occurrence and development of cardiovascular diseases by regulating molecular signals, such as inflammatory response, oxidative stress, insulin resistance/diabetes, endoplasmic reticulum stress, and endothelial dysfunction. Despite extensive research, the underlying molecular mechanisms are still unclear. Allopurinol, a xanthine oxidase (XO) inhibitor, has been shown to improve cardiovascular outcomes in patients with HF, coronary heart disease (CHD), type 2 diabetes (T2D), and left ventricular hypertrophy (LVH). Whether febuxostat, another XO inhibitor, can improve cardiovascular outcomes as well as allopurinol remains controversial. Furthermore, it is also not clear whether UA-lowering treatment (ULT) can benefit patients with asymptomatic hyperuricemia. In this review, we focus on the latest cellular and molecular findings of cardiovascular disease associated with hyperuricemia and clinical data about the efficacy of ULT in patients with cardiovascular disease.

show abstract

Section: Urate-lowering Treatments (Ult)mentioning

confidence: 99%